Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$204.76 USD

204.76
878,984

-0.06 (-0.03%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.

Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News

The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Kevin Cook headshot

Alzheimer's Disease: 5 Stocks on Biotech Radars

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Biogen Inc. (BIIB) Surpasses Q1 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More

The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval

Roche (RHHBY) gains a regulatory nod for its SMA treatment Evrysdi in Europe for patients aged two months and above.

Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails

Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.

AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.

Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation

Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal

Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.

Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod

AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.